Advertisement

Etiology and prognosis of acute respiratory failure in patients with primary malignant brain tumors admitted to the intensive care unit

  • Maxens Decavèle
  • Isabelle Rivals
  • Clémence Marois
  • Marie Cantier
  • Nicolas Weiss
  • Léa Lemasle
  • Hélène Prodanovic
  • Khe Hoang-Xuan
  • Ahmed Idbaih
  • Thomas Similowski
  • Alexandre Demoule
Clinical Study

Abstract

Purpose

Acute respiratory failure (ARF) is common and potentially fatal in patients with primary malignant brain tumors (PMBT). However, few data are available regarding its precipitating factors and prognosis. We sought to: (1) compare the causes of ARF and the outcome between patients with PMBT and patients with other peripheral solid tumors (PST), (2) identify the factors influencing ICU survival in PMBT patients.

Methods

Two-center retrospective case-control study from March 1996 to May 2014. Primary central nervous system lymphomas were also included.

Results

Eighty-four patients with PMBT and 133 patients with PST were included. Acute infectious pneumonia was more frequent in PMBT than PST patients (77 vs. 36%, p < 0.001). Pulmonary embolism was also more frequent in PMBT patients (13% vs. 5%, p = 0.042), while cardiogenic pulmonary edema and acute-on-chronic respiratory failure were more frequent in PST patients (37 vs. 10%, p < 0.001). Among acute infectious pneumonia, Pneumocystis pneumonia and aspiration pneumonia were more frequent in PMBT patients (19 vs. 2%, p < 0.001 and 19 vs. 8%, p < 0.001, respectively). ICU mortality was similar between PMBT and PST patients (24% vs. 24%, p = 0.966). In multivariate analysis, cancer progression (OR 7.25 95% CI 1.13–46.45, p = 0.034), need for intubation (OR 7.01 95% CI 1.29–38.54, p = 0.022), were independently associated with ICU mortality in PMBT patients.

Conclusions

The cause of ARF in patients with PMBT differs significantly than those with PST and up to 50% may have been prevented. Mortality did not differ between the two groups. These results suggest that PMBT alone is not a relevant criterion for ICU recusal.

Keywords

Malignant brain tumors Prognosis Intensive care unit Acute respiratory failure Pneumocystis pneumonia Critical care 

Notes

Acknowledgements

We thank Anthony Saul for his help with English style and grammar

Author Contributions

MD: methodology, data curation, conceptualization, validation, writing - original draft, and writing - review and editing. NW: data curation, conceptualization, validation, writing - original draft. CM: data curation, validation. LL: validation, software. MC: data curation, validation, KH-X: validation. HP: data curation, conceptualization, validation, IR: methodology, software, validation, writing - original draft. AI: supervision, validation, AD: methodology, data curation, supervision, conceptualization, validation, writing - original draft, and writing - review and editing, TS: supervision, validation, conceptualization, writing - original draft.

Compliance with ethical standards

Conflict of interest

Alexandre Demoule has signed research contracts with Covidien, Maquet, Philips and Ait Liquide Santé; he has also received personal fees from Covidien, Maquet and MSD. Ahmed Idbaih reports research funding from La Fondation ARC pour la recherche sur le Cancer, Carthera, Beta-Innov, and Intselchimos; travel funding from Hoffmann-La Roche; and personal fees from Novartis, La Lettre du Cancérologue, BMS, and Cipla unrelated to the submitted work. Nicolas Weiss has signed research contracts with Eumedica, BMS, MedDay pharmaceuticals; he has also received personal fees from Norgine and Alpha-Wasserman. Thomas Similowski has received grant research from Coviden, Philips, Pierre Fabre Médicaments, Air Liquide Medical Systems; he has also received personal fees from Takeda, Teva Pharma, Lungpacer Inc, Almirall France, Pierre Fabre Médicaments, Novartis, Mundipharma, Invacare, Astra Zeneca, Boehringer Ingelheim and GlaxoSmithKline. Hélène Prodanovic, Khê Hoang-Xuan, Clémence Marois, Isabelle Rivals, Marie Cantier, Léa Lemasle and Maxens Decavèle all declare that they have no conflict of interest.

Research involving human participants and/or animals and informed consent.

According to the French Public Health Code (L.1121-1 paragraph 1 and R1121-2,), informed consent is unnecessary for anonymous extraction and analysis of data from patients’ medical charts. The study was approved by the Institutional Review Board of the French Intensive Care Society.

Supplementary material

11060_2018_3074_MOESM1_ESM.docx (84 kb)
Supplementary material 1 (DOCX 83 KB)

References

  1. 1.
    Azoulay E, Thiéry G, Chevret S et al (2004) The prognosis of acute respiratory failure in critically ill cancer patients. Medicine (Baltimore) 83:360–370CrossRefGoogle Scholar
  2. 2.
    Azoulay E, Mokart D, Pène F, Schlemmer B, Chevret S, Lemiale V (2013) Outcomes of critically ill patients with hematologic malignancies: prospective multicenter data from France and Belgium--a groupe de recherche respiratoire en réanimation onco-hématologique study. J Clin Oncol 31:2810–2818CrossRefGoogle Scholar
  3. 3.
    Azoulay E, Lemiale V, Mokart D et al (2014) Acute respiratory distress syndrome in patients with malignancies. Intensive Care Med 40:1106–1114CrossRefGoogle Scholar
  4. 4.
    Azoulay E, Schlemmer B (2006) Diagnostic strategy in cancer patients with acute respiratory failure. Intensive Care Med 32:808–822CrossRefGoogle Scholar
  5. 5.
    Tabouret E, Boucard C, Devillier R, Barrie M, Boussen S, Autran D, Chinot O, Bruder N (2016) Neuro-oncological patients admitted in intensive-care unit: predictive factors and functional outcome. J Neurooncol 127:111–117CrossRefGoogle Scholar
  6. 6.
    Decavèle M, Weiss N, Rivals I et al (2017) Prognosis of patients with primary malignant brain tumors admitted to the intensive care unit: a two-decade experience. J Neurol 264:2303–2312CrossRefGoogle Scholar
  7. 7.
    Mahindra AK, Grossman SA (2003) Pneumocystis carinii pneumonia in HIV negative patients with primary brain tumors. J Neurooncol 63:263–270CrossRefGoogle Scholar
  8. 8.
    Wesling M, Brady S, Jensen M, Nickell M, Statkus D, Escobar N (2013) Dysphagia outcomes in patients with brain tumors undergoing inpatient rehabilitation. Dysphagia 18:203–210Google Scholar
  9. 9.
    Lee WH, Oh BM, Seo HG et al (2016) One-year outcome of postoperative swallowing impairment in pediatric patients with posterior fossa brain tumor. J Neurooncol 127:73–81CrossRefGoogle Scholar
  10. 10.
    Mokart D, Lambert J, Schnell D et al (2013) Delayed intensive care unit admission is associated with increased mortality in patients with cancer with acute respiratory failure. Leuk Lymphoma 54:1724–1729CrossRefGoogle Scholar
  11. 11.
    Louis DN, Perry A, Reifenberger G et al (2016) The 2016 World Health Organization classification of tumors of the central nervous system: a summary. Acta Neuropathol 131:803–820CrossRefGoogle Scholar
  12. 12.
    Vaquero J, Martínez R, Manrique M (2000) Stereotactic biopsy for brain tumors: is it always necessary? Surg Neurol 53:432–437CrossRefGoogle Scholar
  13. 13.
    Oken MM, Creech RH, Tormey DC et al (1982) Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol 5:649–655CrossRefGoogle Scholar
  14. 14.
    Charlson M, Szatrowski TP, Peterson J, Gold J (1994) Validation of a combined comorbidity index. J Clin Epidemiol 47:1245–1251CrossRefGoogle Scholar
  15. 15.
    Le Gall JR, Lemeshow S, Saulnier FA (1993) New simplified acute physiology score (SAPS II) based on a European/North American multicenter study. JAMA 270:2957–2963CrossRefGoogle Scholar
  16. 16.
    Vincent JL, Moreno R, Takala J et al (1996) The SOFA (sepsis-related organ failure assessment) score to describe organ dysfunction/failure. On behalf of the working group on sepsis-related problems of the European Society of intensive care medicine. Intensive Care Med 22:707–710CrossRefGoogle Scholar
  17. 17.
    Gea-Banacloche JC, Opal SM, Jorgensen J, Carcillo JA, Sepkowitz KA, Cordonnier C (2004) Sepsis associated with immunosuppressive medications: an evidence-based review. Crit Care Med 32:S578–S590CrossRefGoogle Scholar
  18. 18.
    Ferreri AJ, Reni M, Foppoli M et al (2009) High-dose cytarabine plus high-dose methotrexate versus high-dose methotrexate alone in patients with primary CNS lymphoma: a randomised phase 2 trial. Lancet 374:1512–1520CrossRefGoogle Scholar
  19. 19.
    Wolach O, Bairey O, Lahav M (2010) Late-onset neutropenia after rituximab treatment: case series and comprehensive review of the literature. Medicine (Baltimore) 2010 89:308–318CrossRefGoogle Scholar
  20. 20.
    Schiff D (1996) Pneumocystis pneumonia in brain tumor patients: risk factors and clinical features. J Neurooncol 27:235–240CrossRefGoogle Scholar
  21. 21.
    Henson JW, Jalaj JK, Walker RW, Stover DE, Fels AO (1991) Pneumocystis carinii pneumonia in patients with primary brain tumors. Arch Neurol 48:406–409CrossRefGoogle Scholar
  22. 22.
    Yale SH, Limper AH (1996) Pneumocystis carinii pneumonia in patients without acquired immunodeficiency syndrome: associated illness and prior corticosteroid therapy. Mayo Clin Proc 71:5–13CrossRefGoogle Scholar
  23. 23.
    Hughes MA, Parisi M, Grossman S, Kleinberg L (2005) Primary brain tumors treated with steroids and radiotherapy: low CD4 counts and risk of infection. Int J Radiat Oncol Biol Phys 62:1423–1426CrossRefGoogle Scholar
  24. 24.
    Sengupta S, Marrinan J, Frishman C, Sampath P (2012) Impact of temozolomide on immune response during malignant glioma chemotherapy. Clin Dev Immunol 2012:831090Google Scholar
  25. 25.
    Lin AJ, Campian JL, Hui C et al (2018) Impact of concurrent versus adjuvant chemotherapy on the severity and duration of lymphopenia in glioma patients treated with radiation therapy. J Neurooncol 136:403–411CrossRefGoogle Scholar
  26. 26.
    Leff RL, Mckenzie R (1990) Rheumatoid arthritis, methotrexate therapy and Pneumocystis pneumonia. Ann Intern Med 112:116CrossRefGoogle Scholar
  27. 27.
    Park DH, Chun MH, Lee SJ, Song YB (2013) Comparison of swallowing functions between brain tumor and stroke patients. Ann Rehabil Med 37:633–641CrossRefGoogle Scholar
  28. 28.
    Wadhwa R, Toms J, Chittiboina P et al (2014) Dysphagia following posterior fossa surgery in adults. World Neurosurg 82:822–827CrossRefGoogle Scholar
  29. 29.
    Lind CD (2003) Dysphagia evaluation and treatment. Gastroenterol Clin N Am 32:553–575CrossRefGoogle Scholar
  30. 30.
    Wrensch M, Minn Y, Chew T et al (2002) Epidemiology of primary brain tumors: current concepts and review of the literature. Neuro Oncol 4:278–299CrossRefGoogle Scholar
  31. 31.
    Petterson TM, Marks RS, Ashrani AA et al (2015) Risk of site-specific cancer in incident venous thromboembolism: a population-based study. Thromb Res 135:472–478CrossRefGoogle Scholar
  32. 32.
    Semrad TJ, O’Donnell R, Wun T et al (2007) Epidemiology of venous thromboembolism in 9489 patients with malignant glioma. J Neurosurg 106:601–608CrossRefGoogle Scholar
  33. 33.
    Sartori MT, Della Puppa A, Ballin A et al (2011) Prothrombotic state in glioblastoma multiforme: an evaluation of the procoagulant activity of circulating microparticles. J Neurooncol 104:225–231CrossRefGoogle Scholar
  34. 34.
    Nalluri SR, Chu D, Keresztes R et al (2008) Risk of venous thromboembolism with the angiogenesis inhibitor bevacizumab in cancer patients: a meta-analysis. JAMA 300:2277–2285CrossRefGoogle Scholar
  35. 35.
    Green H, Paul M, Vidal L, Leibovici L (2007) Prophylaxis of pneumocystis pneumonia in immunocompromised non-HIV-infected patients: systematic review and meta-analysis of randomized controlled trials. Mayo Clin Proc 82:1052–1059CrossRefGoogle Scholar
  36. 36.
    Stupp R, Brada M, van den Bent MJ, Tonn JC, Pentheroudakis G, ESMO Guidelines Working Group.(2014) High-grade glioma ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 25:93–101CrossRefGoogle Scholar
  37. 37.
    Hoang-Xuan K, Bessell E, Bromberg J et al (2015) European association for Neuro-Oncology task force on primary CNS lymphoma. Diagnosis and treatment of primary CNS lymphoma in immunocompetent patients: guidelines from the European association for Neuro-Oncology. Lancet Oncol 16:e322–e332CrossRefGoogle Scholar
  38. 38.
    Lyman GH, Bohlke K, Khorana AA et al (2015) Venous thromboembolism prophylaxis and treatment in patients with cancer: american society of clinical oncology clinical practice guideline Update 2014. J Clin Oncol 33:654–656CrossRefGoogle Scholar
  39. 39.
    Dennis MS, Lewis SC, Warlow C (2005) FOOD Trial Collaboration: Effect of timing and method of enteral tube feeding for dysphagic stroke patients (FOOD): a multicentre randomised controlled trial. Lancet 365:764–772CrossRefGoogle Scholar
  40. 40.
    Troche MS, Okun MS, Rosenbek JC et al (2010) Aspiration and swallowing in Parkinson disease and rehabilitation with EMST: a randomized trial. Neurology 75:1912–1919CrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC, part of Springer Nature 2018

Authors and Affiliations

  • Maxens Decavèle
    • 1
    • 2
  • Isabelle Rivals
    • 1
    • 3
  • Clémence Marois
    • 2
  • Marie Cantier
    • 2
  • Nicolas Weiss
    • 4
  • Léa Lemasle
    • 2
  • Hélène Prodanovic
    • 2
  • Khe Hoang-Xuan
    • 5
  • Ahmed Idbaih
    • 5
  • Thomas Similowski
    • 1
    • 2
  • Alexandre Demoule
    • 1
    • 2
  1. 1.Sorbonne Universités, UPMC Univ Paris 06, INSERM, UMRS_1158 Neurophysiologie respiratoire expérimentale et cliniqueParisFrance
  2. 2.AP-HP, Groupe Hospitalier Pitié-Salpêtrière Charles Foix, Service de Pneumologie et Réanimation Médicale (Département “R3S”)ParisFrance
  3. 3.Equipe de Statistique Appliquée, ESPCI Paris, PSL Research University, UMRS 1158 Neurophysiologie Respiratoire Expérimentale et CliniqueParisFrance
  4. 4.Sorbonne Université, Brain Liver Pitié-Salpêtrière (BLIPS) Study Group, INSERM UMR_S 938, Centre de Recherche Saint-Antoine, Assistance Publique - Hôpitaux de Paris, Groupement Hospitalier Pitié-Salpêtrière Charles Foix, Département de Neurologie, Unité de réanimation neurologiqueParisFrance
  5. 5.Sorbonne Université, Inserm, CNRS, UMR S 1127, Institut du Cerveau et de la Moelle épinière, ICM, AP-HP, Hôpitaux Universitaires La Pitié Salpêtrière - Charles FoixParisFrance

Personalised recommendations